Navigation Links
European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Date:9/24/2007

sease who have not been previously treated with interferon alpha and who are at least 18 years of age. PEGINTRON is not indicated in the United States for retreatment of patients who failed previous interferon therapy.

Important Safety Information Regarding U.S. Labeling for PEGINTRON and REBETOL

Alpha interferons, including PEGINTRON and INTRON(R) A, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy. In many, but not all cases, these disorders resolve after stopping PEGINTRON and/or INTRON A therapy.

Use with Ribavirin: Ribavirin may cause birth defects and/or death of the unborn child. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin causes hemolytic anemia. The anemia associated with REBETOL therapy may result in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a potential carcinogen

Contraindications

PEGINTRON is contraindicated in patients with hypersensitivity to PEGINTRON or any other component of the product, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6 [class B and C]) in cirrhotic CHC patients before or during treatment. INTRON A (Interferon alfa- 2b, recombinant) for Injection is contraindicated in patients with hypersensitivity to INTRON A or any component of the product, autoimmune hepatitis, and decompensated liver disease. PEGINTRON or INTRON A in combination with REBETOL therapy is additionally contraindicated in patients with hypersensitivity to ribavirin or any other component of the product, women who are pregnant, men whose female partners are pregnant, patients with hemoglobinopathies (e.g., thalassemia
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. Malvern initiates European user group meetings for chemical imaging
7. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
8. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
9. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
10. Inspire Announces Presentations at Two European Scientific Conferences
11. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... FRAMINGHAM, Mass. , Jan. 14, 2014 ... a leading innovator of less invasive, miniaturized circulatory support ... failure, today announced that it expects revenues for the ... bringing expected full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis ... affordable laser tattoo removal experience with the advanced Astanza Duality laser ... high quality cosmetic services with cutting edge medical technology and offering ... California has seen a dramatic increase in the presence ...
(Date:1/14/2014)... Animal Emergency Critical Care, a LifeCentre partner practice, located at ... is the first in Loudoun County to ... Susan M. Barnes , Medical Director, is a well-seasoned veterinarian ... Cole Taylor , are avid scuba divers. "As altitude skiers and ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... Three Independent Clinical Trials Initiated with Teplizumab Manufactured at ... ... that its Protege trial is actively enrolling adults and children ages,8 to ... evaluate the safety and efficacy of three teplizumab dosing,regimens administered at the ...
... versus 26.2 for ... Vidaza compared to ... conventional ... modifier to show survival benefit in cancer Stratified log-rank p-value = 0.0001, Hazard ...
Cached Medicine Technology:MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus 2MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus 3MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus 4Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 2Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 3Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 4Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 5Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 6Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 7Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 8
(Date:7/9/2014)... common type of lung cancer, researchers have uncovered mutations ... forming tumors. The new knowledge may expand treatments for ... already are available or are in clinical trials. , ... The Cancer Genome Atlas (TCGA), including researchers at Washington ... School and other institutions, studied tumors from 230 patients ...
(Date:7/9/2014)... Researchers have found that fecal transplantation is effective ... immunocompromised patients. This is the result of a study ... Center for Women,s Gastrointestinal Medicine at The Women,s Medicine ... online in advance of print in the American ... or C. diff , has increased to epidemic ...
(Date:7/9/2014)... N.Y. Although feelings are personal and subjective, ... code that objectively represents emotions across different senses, ... by Cornell University neuroscientist Adam Anderson. , "We ... the orbitofrontal cortex, an area of the brain ... code which captures an individual,s subjective feeling," says ...
(Date:7/9/2014)... from Montefiore Medical Center and the ... will present new findings at the Alzheimer,s Association International ... in Copenhagen, Denmark. Data from the four abstracts will ... normality to mild cognitive impairment and dementia. The research ... established in 1980 to examine healthy brain aging as ...
(Date:7/9/2014)... have a reputation for being highly toxic, but when used ... being found to offer potential health benefits in a range ... A new compound (AP39), designed and made at the University ... targeting delivery of very small amounts of the substance to ... in Exeter have already found that the compound protects mitochondria ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:Study cracks how the brain processes emotions 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Rotten egg gas holds key to healthcare therapies 2
... to debate on the supplement but doesn,t settle it, one ... Glucosamine sulfate, a popular dietary supplement purported to ease the ... people with arthritis in their hips. , That,s the conclusion ... a placebo for the treatment of mild to moderate hip ...
... named the,fastest growing PR agency in the U.S., announced ... Symposium," showcasing exclusive consumer,brands from 5W,s Health & Beauty ... April 22nd from 10 a.m. to 2 p.m. at ... Hearst building and near the Time,Warner Center., This ...
... to Industry Best-Practices, MINNEAPOLIS, Feb. ... established national healthcare consulting practice, has ... which a PBM or Health,Plan can ... core organizational quality, customer service, communications ...
... Radiology Group (FRG),and the Brownsville Tri-County Hospital have ... Brownsville,s exclusive provider of,diagnostic imaging services., "The ... work,with," stated Richard W. Hritz, CEO of the ... involvement in working to bring this,hospital back online, ...
... 18 In rural Milledgeville,Georgia, 62 year old insulin-dependent ... 10,000+ mile perimeter walk of the United,States raising awareness ... "I,ve hit milestones in San Diego, Seattle, Chicago, Boston, ... of diabetes, only,fewer resources to manage it. We can ...
... Feb. 18 Be aware, be,prepared and take ... State University trauma expert on,preventing tragedies like the ... Briana Nelson Goff, associate dean of K-State,s College ... and human services,leads the Trauma Research, Education and ...
Cached Medicine News:Health News:Study Suggests Glucosamine Won't Ease Hip Arthritis 2Health News:Study Suggests Glucosamine Won't Ease Hip Arthritis 3Health News:5W Public Relations Hosts Exclusive Beauty & Wellness Industry Event 2Health News:Halleland Health Consulting Assists PBMs in Achieving URAC Accreditation for Pharmacy Benefit Management 2Health News:Foundation Radiology Group and Brownsville Tri-County Hospital Sign Long-Term Contract for Diagnostic Imaging Services 2Health News:Foundation Radiology Group and Brownsville Tri-County Hospital Sign Long-Term Contract for Diagnostic Imaging Services 3Health News:Mr. Diabetes(R) Hits 9,000 Mile Mark of 10,000+ Mile Walk to Raise Awareness About Diabetes 2Health News:K-State Trauma Researcher Says Being Prepared, Taking Action Are Vital in Preventing Tragedies Like the One at NIU 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: